Brief: Affimed presents data on potency of NK- and T-cell EGFRvIII tandabs

Affimed NV

06/11/2015 10:02

Nov 6 (Reuters) - Affimed NV  AFMD.O : 
 * Presents data on potency of nk- and t-cell egfrviii tandabs 
 * Results showed co's tandabs against egfrviii, afm21 and afm22 were similarly 
   potent as measured in killing assays, displaying cytotoxicity 
 * Says both the nk- and t-cell tandabs against egfrviii will be further 
   investigated for candidate selection 
 * Affimed anticipates candidate selection to take place around year-end 2015; 
   ind-enabling studies are expected to begin in 2016 
 
 * Source text for Eikon  ID:nGNXVETXJa  
 * Further company coverage  AFMD.O  
 
 ((Bengaluru Newsroom; +1 646 223 8780))